Parsatuzumab, CAS 1312797-14-0

Product Description: Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody, acts as an immunomodulator and binds to EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition[1].

Applications: Cancer-Kinase/protease

Formula: N/A

References: [1]García-Carbonero R, et al. Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer. Oncologist. 2017 Apr;22(4):375-e30. /[2]Chinmayee Goda, et al. Dorrance, Epidermal Growth Factor-like 7 As a Novel Therapeutic Target in Mantle Cell Lymphoma. Blood. 138(S1), 2021:3300.

CAS Number: 1312797-14-0

Molecular Weight: N/A

Compound Purity: 96.52

Research Area: Cancer

Solubility: 10 mM in DMSO

Target: VEGFR

• Artikelnummer: MEXHY-P99215-10
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99215-10
• Green Labware: Nein
• Verpackungseinheit: 10 mg
• Mengeneinheit: STK